The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma.
published in: Leukemia Research
date of publication: 2017-01-12
Cites articles 43
- 2005-03-01
Date
Title
Article - wd:Q51170783
Article - wd:Q51170783